Table 1. Biological parameters at the end of the 20-week study

ParametersControl C57BL/6 (n = 20)Diabetic C57BL/6 (n = 20)Control apo E-KO (n = 20)Diabetic apo E-KO (n = 20)Diabetic apo E-KO + Aminoguanidine (n = 20)Diabetic apo E-KO + ALT-711 (n = 13)
a Data are mean ± SEM. apo E-KO, apolipoprotein E knockout; SBP, systolic BP; HbA1c, glycated hemoglobin.
b P < 0.05, c P < 0.01 versus appropriate nondiabetic control group.
d P < 0.05, e P < 0.01 versus appropriate C57BL/6 group.
f P < 0.05, g P < 0.01 versus diabetic apo E-KO mice.
h P < 0.01 versus diabetic apo E-KO mice treated with aminoguanidine.
Body weight (g)31 ± 123 ± 1c30 ± 121 ± 0.3c22 ± 121 ± 1
Kidney weight/body weight (g/kg)6.42 ± 0.219.17 ± 0.16c7.27 ± 0.508.78 ± 0.45b8.16 ± 0.237.71 ± 0.35
HbA1c (%)3.3 ± 0.313.0 ± 1.0c3.8 ± 0.113.0 ± 0.4c12.1 ± 0.414.4 ± 1.1h
SBP (mmHg)100 ± 398 ± 4117 ± 2e117 ± 5e125 ± 3123 ± 3
Plasma cholesterol (mmol/L)1.8 ± 0.22.0 ± 0.214.3 ± 0.4e35.6 ± 2.4c,e31.6 ± 1.228.6 ± 2.2f
Plasma triglycerides (mmol/L)0.76 ± 0.091.152 ± 0.20b0.89 ± 0.071.86 ± 0.29c,d2.00 ± 0.301.43 ± 0.20
Plasma creatinine (μmol/L)16 ± 221 ± 313 ± 235 ± 3c,d30 ± 237 ± 2
Plasma urea (mmol/L)8.8 ± 1.513.8 ± 1.3b8.7 ± 0.612.3 ± 1.1b13.5 ± 1.113.5 ± 0.5